Citation

Gastaldon C, Laurenzi PF, Schoretsanitis G, Papola D, Cristea IA, Naudet F, Ostuzzi G, Barbui C. Cochrane Database Syst. Rev. 2022; 2022(1).

Copyright

(Copyright © 2022, The Cochrane Collaboration, Publisher John Wiley and Sons)

DOI

10.1002/14651858.CD015071

PMID

unavailable

Abstract

OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression. Secondary aims are to assess the risk of specific adverse events during esketamine treatment, and its acceptability. Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Language: en

Keywords

adult; human; suicide; systematic review; Review; suicidal ideation; anxiety; suicide attempt; treatment outcome; dissociative disorder; vomiting; sedation; headache; vertigo; drug safety; information processing; drug efficacy; meta analysis; drug tolerability; nausea; hypertension; data analysis; side effect; sensitivity analysis; agitation; dizziness; data extraction; dysgeusia; abnormal sensation; data synthesis; treatment resistant depression; statistical bias; elevated blood pressure; esketamine